Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

A Phase 1 Study to Assess Pharmacokinetics (PK) and Safety of Ixazomib, an Oral Proteasome Inhibitor, in Patients with Moderate or Severe Hepatic Impairment

Neeraj Gupta, PhD, Michael J Hanley, PhD, Karthik Venkatakrishnan, PhD, Raymond Perez, MD, Robin E Norris, MD, John Nemunaitis, MD, Huyuan Yang, PhD, Gerald Falchook, MD, Richard Labotka, MD MS, Siqing Fu, MD PhD

Blood (2015) 126 (23): 3032.

https://doi.org/10.1182/blood.V126.23.3032.3032

Published: 2015

Journal Articles

Phase 1/1b Pharmacokinetic (PK) and Safety Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Severe Renal Impairment or End-Stage Renal Disease (ESRD) Requiring Hemodialysis

Neeraj Gupta, PhD, Michael J Hanley, PhD, R. Donald Harvey, PharmD, Ashraf Z Badros, MD, Brea C. Lipe, MD, Vishal Kukreti, Jesus G. Berdeja, MD, Huyuan Yang, PhD, Ai-Min Hui, MD PhD, Xiaoquan Zhang, MD PhD, Karthik Venkatakrishnan, PhD, Ajai Chari, MD

Blood (2015) 126 (23): 4227.

https://doi.org/10.1182/blood.V126.23.4227.4227

Published: 2015

Journal Articles

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics

Philippe Moreau, MD, Ievgenii I Karamanesht, MD, Natalia Domnikova, Maryna Y Kyselyova, MD, Kateryna Vilchevska, Vadim A Doronin, MD, PhD, Alexander Schmidt, MD, Cyrille Hulin, MD, Xavier Leleu, MD, PhD, Dixie-Lee Esseltine, MD, FRCPC, Karthik Venkatakrishnan, Donna M Skee, BS, Huaibao Feng, PhD, Suzette Girgis, Andrew Z Cakana, MD, FRCPath, William M Deraedt, PhD, Thierry Facon, MD

Blood (2011) 118 (21): 1863.

https://doi.org/10.1182/blood.V118.21.1863.1863

Published: 2011

Journal Articles

Flat-Dosing Versus BSA-Based Dosing for MLN9708, An Investigational Proteasome Inhibitor: Population Pharmacokinetic (PK) Analysis of Pooled Data From 4 Phase-1 Studies

Neeraj Gupta, PhD, Mohammad Saleh, Karthik Venkatakrishnan

Blood (2011) 118 (21): 1433.

https://doi.org/10.1182/blood.V118.21.1433.1433

Published: 2011

Journal Articles

Pharmacokinetics and Safety of Bortezomib In Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Results of the Phase 1 National Cancer Institute Organ Dysfunction Working Group Study NCI 6432

Karthik Venkatakrishnan, Ramesh K Ramanathan, John Sarantopoulos, Daniel L Mulkerin, Stephen I Shibata, Anne Hamilton, Afshin Dowlati, Sridhar Mani, Michelle A Rudek, Percy Ivy, Chris H Takimoto, Rachel Neuwirth, Sudha Parasuraman, Patricia M LoRusso

Blood (2010) 116 (21): 3975.

https://doi.org/10.1182/blood.V116.21.3975.3975

Published: 2010

Journal Articles

Phase 1 Dose-Escalation Study of MLN4924, a Novel NAE Inhibitor, in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.

Jatin J Shah, Andrzej J Jakubowiak, Owen A O’Connor, Robert Z Orlowski, Molly Patterson, Donald Harvey, Allison J Berger, Alice McDonald, George Mulligan, Lilli Petruzzelli, Michael D Pickard, Peter G Smith, Karthik Venkatakrishnan, Sagar Lonial

Blood (2009) 114 (22): 1854.

https://doi.org/10.1182/blood.V114.22.1854.1854

Published: 2009

NARROW

A Phase 1 Study to Assess Pharmacokinetics (PK) and Safety of Ixazomib, an Oral Proteasome Inhibitor, in Patients with Moderate or Severe Hepatic Impairment

Phase 1/1b Pharmacokinetic (PK) and Safety Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Severe Renal Impairment or End-Stage Renal Disease (ESRD) Requiring Hemodialysis

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics

Flat-Dosing Versus BSA-Based Dosing for MLN9708, An Investigational Proteasome Inhibitor: Population Pharmacokinetic (PK) Analysis of Pooled Data From 4 Phase-1 Studies

Pharmacokinetics and Safety of Bortezomib In Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Results of the Phase 1 National Cancer Institute Organ Dysfunction Working Group Study NCI 6432

Phase 1 Dose-Escalation Study of MLN4924, a Novel NAE Inhibitor, in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

A Phase 1 Study to Assess Pharmacokinetics (PK) and Safety of Ixazomib, an Oral Proteasome Inhibitor, in Patients with Moderate or Severe Hepatic Impairment

Phase 1/1b Pharmacokinetic (PK) and Safety Study of the Investigational Oral Proteasome Inhibitor (PI) Ixazomib in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) with Severe Renal Impairment or End-Stage Renal Disease (ESRD) Requiring Hemodialysis

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics

Flat-Dosing Versus BSA-Based Dosing for MLN9708, An Investigational Proteasome Inhibitor: Population Pharmacokinetic (PK) Analysis of Pooled Data From 4 Phase-1 Studies

Pharmacokinetics and Safety of Bortezomib In Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Results of the Phase 1 National Cancer Institute Organ Dysfunction Working Group Study NCI 6432

Phase 1 Dose-Escalation Study of MLN4924, a Novel NAE Inhibitor, in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only